Pierre-Etienne joined the Horowitz laboratory in October 2025 as a visiting researcher as part of his doctoral training. He is currently pursuing a PhD in oncogenesis within Inserm Unit U976 at the Saint-Louis Hospital Research Institute in Paris, under the supervision of Prof. Evanguelos Xylinas.

He obtained his MD degree in 2019 from Sorbonne University, followed by a transversal specialized training in oncology, and completed a Master of Science at Université Paris-Saclay in 2023, focusing on the prognostic and predictive value of mismatch repair protein loss in patients with upper tract urothelial carcinoma. From 2024 to 2025, he served as a junior doctor in urology at Bichat–Claude Bernard Hospital, Université Paris Cité, under the chairmanship of Prof. Jean-François Hermieu.

His translational research focuses on urothelial bladder cancer, with a particular interest in identifying biomarkers of response and resistance in non–muscle-invasive bladder cancer using integrated molecular and immunological approaches. At Mount Sinai, his current research explores dual immunotherapy targeting the HLA-E/NKG2A and PD-1/PD-L1 pathways in BCG-unresponsive non–muscle-invasive bladder cancer, biomarkers of response and resistance to gemcitabine/docetaxel, and the biological determinants of response to enfortumab vedotin–pembrolizumab.

Fun fact: I try a different burger every week to create a ranking of the best burgers in New York.